CRVSMEDIUM SIGNALFINANCIAL10-K

CRVS advanced its lead drug candidate soquelitinib from Phase 1 to Phase 2 trials while significantly strengthening its balance sheet through reduced liabilities and improved equity position.

The company's clinical progress with soquelitinib moving into Phase 2 for atopic dermatitis represents meaningful advancement in its pipeline development. However, investors should note the substantially higher R&D expenses and increased operating losses, indicating elevated cash burn as the company pursues more expensive later-stage trials.

Comparing 2026-03-12 vs 2025-03-25View on EDGAR →
FINANCIAL ANALYSIS

CRVS demonstrated a notably improved balance sheet with stockholders' equity growing to $61.2M while total liabilities declined meaningfully to $9.9M, suggesting successful equity financing or debt reduction. Operating performance deteriorated with operating losses expanding and R&D expenses growing substantially, reflecting increased investment in clinical development. The company's cash position declined moderately to $4.6M, which combined with higher operating losses, raises questions about funding runway for continued clinical operations.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
+87.9%
$32.6M→$61.2M

Equity base grew 87.9% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Net Income
P&L
+75.5%
-$62.3M→-$15.3M

Net income grew 75.5% — bottom-line growth signals improving overall business health.

R&D Expense
P&L
+73.9%
$19.4M→$33.7M

R&D investment increased 73.9% — signals commitment to future product development, though near-term margin impact.

Current Liabilities
Balance Sheet
-73.5%
$35.4M→$9.4M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Liabilities
Balance Sheet
-72.7%
$36.3M→$9.9M

Liabilities reduced 72.7% — deleveraging improves balance sheet strength and financial flexibility.

Operating Income
P&L
-56%
-$27.5M→-$43.0M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Accounts Receivable
Balance Sheet
-50.7%
$75K→$37K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Cash & Equivalents
Balance Sheet
-47.6%
$8.7M→$4.6M

Cash declined 47.6% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Cash Flow
Cash Flow
-29%
-$25.4M→-$32.8M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-25
ADDED
As of March 12, 2026, 83,992,407 shares of the registrant s common stock were outstanding.
Given these uncertainties, you should not place undue reliance on these forward-looking statements.
We believe our proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers.
Soquelitinib entered both a registrational, Phase 3 clinical trial for relapsed T cell lymphomas and a recently initiated randomized, placebo-controlled Phase 2 trial in patients with atopic dermatitis.
Product Candidate Pipeline Our product candidate pipeline and anticipated milestones include the following: (1) The Company did not conduct Phase 1 studies for these specific indications, but is planning to initiate Phase 2 studies for these indications based on the Phase 1 Atopic Dermatitis study.
Inhibition of ITK with soquelitinib could result in blockade of this signaling pathway and control the growth of the malignancy.
Selective inhibition of ITK can block the production and function of Th2 and Th17 helper T cells, potentially leading to a biasing toward the differentiation of na ve T cells into Th1 helper T cells.
Key results from the publication include that soquelitinib: Selectively bound to and inhibited ITK function while sparing other closely related kinases, including resting lymphocyte kinase.
Soquelitinib is currently being studied both in cancer and in immune mediated diseases.
The study is now complete, however, some of the patients remain on therapy and are continuing to receive follow-up monitoring.
REMOVED
As of March 25, 2025, 68,135,796 shares of the registrant s common stock were outstanding.
We believe our proprietary product candidates have broad potential to address cancers, immune mediated diseases and inflammatory diseases.
Soquelitinib entered a registrational, Phase 3 clinical trial for relapsed T cell lymphomas and is also being evaluated in a randomized, placebo controlled Phase 1 trial in patients with atopic dermatitis.
Product Pipeline Our product candidate pipeline and anticipated milestones include the following: Soquelitinib (CPI-818), ITK Inhibitor.
In addition, one of the key survival mechanisms of both lymphomas and solid tumors is believed to be the reprogramming of normal T cells to create an environment in the tissues that inhibits an anti-tumor immune response and favors tumor growth.
Selective inhibition of ITK can block the production and function of Th2 and Th17 helper T cells, potentially leading to a biasing toward the differentiation of na ve T cells into Th1 helper T cells, a process known as Th1 skewing.
Soquelitinib is currently being studied both in cancer and in immune mediated disease.
A Phase 1/1b clinical trial was conducted in patients with relapsed T cell lymphomas that was designed to select the optimal dose of soquelitinib and evaluate its safety, pharmacokinetics ( PK ), target occupancy, immunologic effects, biomarkers and efficacy.
The study is no longer enrolling new patients, however, some of the patients remain on therapy and are continuing to receive follow-up monitoring.
The study employs an adaptive, expansion cohort design, with an initial phase that evaluated escalating doses (100, 200, 400 or 600 mg taken twice a day) in successive cohorts of patients, followed by a second phase that was designed to evaluate safety and tumor response to the recommended dose of soquelitinib in disease-specific patient cohorts.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →